In NF-1–associated gliomas, MEK inhibition has demonstrated partial efficacy in NF1-mutant gliomas (11, 15), and combined BRAF/MEK inhibition has proven effective in BRAF p.V600E mutant gliomas (16), further supporting the translational potential of Ras/RAF/MEK/ERK blockade within genetically defined glioma subtypes. This evidence concerns the gene MAP2K7 and central nervous system cancer.